Anti-Vista Antibodies And Fragments, Uses Thereof, And Methods Of Identifying Same
AssigneeJanssen Pharmaceutica NV
InventorsLinda A. Snyder, Gordon Powers, Enrique Zudaire Ubani, Douglas Matthew Marvel
Life of this patent
Estimating the term…
Abstract
The present invention relates to antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of eliciting certain biological responses using the antibodies. Compositions and methods of using anti-VISTA antibodies in combination with one or more antibodies that bind to immune checkpoint proteins are also provided.
Claims31
A pharmaceutical composition comprising:
- a) an antibody or antibody fragment thereof comprising an antigen binding region that binds to a V-domain Ig Suppressor of T cell Activation (VISTA);
- b) an antibody or antibody fragment thereof comprising an antigen binding region that binds to an immune checkpoint protein;
- and
- c) a pharmaceutically acceptable carrier, diluent, or excipient.
A pharmaceutical composition comprising:
- a) an antibody or antibody fragment thereof comprising an antigen binding region that binds to a V-domain Ig Suppressor of T cell Activation (VISTA);
- b) an antibody or antibody fragment thereof comprising an antigen binding region that binds to a PD-1 protein;
- and
- c) a pharmaceutically acceptable carrier, diluent, or excipient.
A method of enhancing an immune response in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of:
- a) an antibody or an antibody fragment thereof comprising an antigen binding region that binds V-domain Ig Suppressor of T cell Activation (VISTA);
- and
- b) an antibody or antibody fragment thereof comprising an antigen binding region that binds to an immune checkpoint protein,
- thereby enhancing an immune response to the cancer.
Dependencies are inferred from the claim text.